We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
-5.69%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$483M
AUM Growth
-$120M
Cap. Flow
-$26M
Cap. Flow %
-5.39%
Top 10 Hldgs %
96.08%
Holding
14
New
4
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
APTX
Aptinyx Inc. Common Stock
APTX
+$68.3M
2
ITRM
Iterum Therapeutics
ITRM
+$18.5M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.2M
4
KZR
Kezar Life Sciences
KZR
+$4.36M
5
SYBX
Synlogic
SYBX
+$940K

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$115M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$11.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.7B
$165M 34.09%
2,316,447
-1,372,001
-37% -$115M
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
$77.1M 15.97%
+3,190,079
New +$68.3M
COLL icon
3
Collegium Pharmaceutical
COLL
$820M
$45M 9.32%
1,887,332
– –
ALNA
4
DELISTED
Allena Pharmaceuticals
ALNA
$43.4M 8.99%
3,330,373
– –
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$40.6M 8.41%
2,600,014
– –
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.74B
$28M 5.8%
2,188,331
– –
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$24M 4.97%
202,803
– –
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$16.6M 3.45%
2,199,011
– –
ITRM
9
DELISTED
Iterum Therapeutics
ITRM
$16.4M 3.4%
+102,554
New +$18.5M
SYBX
10
DELISTED
Synlogic
SYBX
$8.07M 1.67%
54,765
+5,853
+12% +$940K
BLCM
11
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7.76M 1.61%
+105,144
New +$8.2M
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$6.82M 1.41%
65,613
– –
KZR
13
DELISTED
Kezar Life Sciences
KZR
$4.33M 0.9%
+25,000
New +$4.36M
ARMO
14
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
– –
-300,000
Closed -$11.2M

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q2 2018 Portfolio in Review

As of Q2 2018, Frazier Management held 14 positions worth $483M, down 20% from $603M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Frazier Management withdrew a net $26M in Q2 2018, closing 1 position and reducing 1 holding. Its most notable exit was ARMO BioSciences, Inc. Common Stock, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Frazier Management opened a new position in Aptinyx Inc. Common Stock worth $77.1M.

  • Frazier Management's largest Q2 2018 buy was Aptinyx Inc. Common Stock: 3,190,079 shares worth $77.1M.
  • Frazier Management added most to Synlogic in Q2 2018, an estimated $940K increase.
  • Frazier Management's biggest Q2 2018 reduction was AnaptysBio, cutting an estimated $115M.
  • Frazier Management fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $11.2M.
  • Frazier Management's ten largest holdings make up 96% of its $483M portfolio in Q2 2018.
  • Frazier Management opened 4 new positions and closed 1 in Q2 2018.
  • Frazier Management's portfolio value fell 20% quarter-over-quarter to $483M.

Based on Frazier Management's 13F filing for Q2 2018, filed 15 Aug 2018.